Innovus Pharma Enters $1 Billion Worldwide Nasal Steroid Market with the Acquisition of Fluticare(tm) (Fluticasone Propionate Nasal) over the Counter ("otc") Rights from Novalere
Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today that it acquired the worldwide rights to the Fluticare(TM) brand (Fluticasone propionate nasal spray) from Novalere FP., Inc. ("Novalere") through a merger.
View full press release